Pharmacologic therapy of severe heart failure

Improvement of symptoms and, accordingly, quality of life, as well as prolongation of life, are the objectives of drug therapy in congestive heart failure patients. Diuretics are most effective in relieving symptoms related to congestion, and angiotensin converting enzyme inhibitors improve exercise capacity, reduce the incidence of decompensations and hence hospitalizations, and prolong life. Angiotensin type-1 receptor antagonists also seem to improve survival, while digoxin improves symptoms and morbidity but not survival in patients in sinus rhythm. The value of prophylactic antiarrhythmic therapy with amiodarone and oral anticoagulation in the presence of sinus rhythm is not established, and the role of newer dihydropyridine calcium antagonists and betablockers is also not precisely defined. These agents should only be considered in selected cases after careful consideration of potential advantages and risks, and should usually be used as an addition to established therapy. Better understanding of the pathophysiology of congestive heart failure will lead to the development of new treatment concepts, the clinical relevance of which will have to be tested in appropriately designed clinical trials.     

Pharmacologic therapy of asthma during pregnancy

Asthma is a common, potentially serious medical complication during pregnancy. Optimal clinical and pharmacologic management is necessary to mitigate maternal and fetal complications. Mild asthma may be managed in most cases with inhaled beta 2-mimetics. Anti-inflammatory therapy is recommended for the treatment of moderate and severe asthma. Based on limited human experience, beclomethasone is currently the recommended inhaled corticosteroid during pregnancy. However, other inhaled corticosteroids may have advantages compared to beclomethasone because of reduced systemic absorption, which may adversely affect intrauterine growth. Based upon theoretic considerations, theophylline is now considered a secondary therapy, but data demonstrating the superiority of inhaled corticosteroids versus theophylline during pregnancy are lacking.     

Pharmacologic and non-pharmacologic therapy of ventricular tachyarrhythmias

One of the main causes of cardiovascular death is the sudden death which is most frequently caused by malign arrhythmias: ventricular tachycardia (VT) and ventricular fibrillation (VF). These fatal disorders of rhythm are not manageable effectively by surgery, catheter ablation and pharmacology which cannot be thus widely used. Automatic implantable cardiovertors-defibrillators (AICD) have been used since 1980 in the therapy of malign ventricular disorders of rhythm. Modern AICD in more severe ventricular arrhyhmias have reduced the frequency of sudden death from 10-30% yearly to 1%. Our objective was to use preferentially the best therapy possible with the least demanding output and the smallest postoperative risk, i.e. therapy with transvenous AICD. This was enabled by new apparatuses-Phylax 03 and Phylac 06 which are able to give the defibrillation shock by iridium covered electrodes also without subcutaneous so called "patch" electrodes. These circumstances result in a suitable defibrillation threshold. (Fig. 2, Ref. 14.)     

Pharmacologic therapy of cranio-cervico-mandibular disorders. Review of the literature

Enzymes are essential to life and catalyze various metabolic activities. They find application in a number of diseased conditions, and their scope is being widened as knowledge develops.     

Screening of prostate cancer in males with prostatism

Genetic analysis of the population structure of the western blacklegged tick, Ixodes pacificus Cooley & Kohls, was conducted using allozymes. This vector tick transmits the Lyme disease spirochete, Borrelia burgdorferi Johnson, Schmid, Hyde, Steigerwalt & Brenner, in the far-western United States. It ranges from British Columbia to Baja California and disjunct populations are present in Oregon, Nevada, Utah, and Arizona. Host-seeking adult ticks were collected from vegetation across the range of the species and were partially fed on rabbits prior to analysis. Twelve putative loci were resolved using starch gel electrophoresis. One locus, glucose-6-phosphate isomerase, formed an apparent north/south latitudinal cline and showed significant geographic structure. None of the remaining loci exhibited much genetic differentiation. Estimates of gene flow were high relative to other arthropods. Isolation-by-distance analysis suggests a recent and rapid range expansion. We conclude that the overall lack of differentiation is due high rates of gene flow.     

Pharmacologic control of a humanized gene therapy system implanted into nude mice

Systemic delivery of specific therapeutic proteins by a parenteral route of administration is a recognized practice in the management of several gene defects and acquired diseases. As an alternative to repetitive parenteral administration, gene therapy may provide a novel means for systemic delivery of therapeutic proteins while improving patient compliance and therapeutic efficacy. However, for gene therapy to be an efficacious and safe approach to the clinical management of such diseases, gene expression must be tightly regulated. These investigations demonstrate precise in vivo control of protein expression from cells that are engineered to secrete human growth hormone (hGH) in response to stimulation by rapamycin. The cells were implanted intramuscularly into nu/nu mice and stimulated by intravenous or oral administration of rapamycin. In vivo experiments demonstrate that the activity and pharmacokinetics of rapamycin determine the level of serum hGH that result from the engineered cells. In addition, responsiveness of the cells to rapamycin, number of cells implanted, hGH expression kinetics, and the pharmacokinetics of hGH itself, also influence the circulating levels of hGH after rapamycin stimulation. Controlled manipulation of several of these parameters, either independently or in combination, allows for precise regulation of circulating hGH concentration in vivo.     

Pharmacologic therapies

Medical treatment of low back pain is at best palliative. While no drugs are specifically labeled for back pain treatment, analgesics, muscle relaxants, and corticosteroids are used in practice to augment rest and exercise programs. Invasive therapy remains contentious. This article reviews the available literature on the various pharmacologic therapies. In addition, newly postulated outcome measures for future back pain studies are discussed.     

Role of a urology nurse in evaluating patients with prostatism

Motor rehabilitation alone is considered and effective treatment for patients affected by claudicatio intermittens although underlying diseases may often influence but not exclude its efficacy. According to the literature no agreement exists about rehabilitative methods. The authors, in order to contribute to a standardization of rehabilitative methods, report their experience characterized by good results. Moreover, the authors stress the importance of the treatment in desisting from habits like cigarette smoking.     

Pharmacologic pain treatment

Pharmacotherapy of chronic pain uses the following groups of drugs: simple analgesics, NSAID's, opioids, calcitonin, antidepressants, neuroleptic drugs and myorelaxants. Diseases of the locomotor system are very often chronic or chronically recurrent. We therefore need a tailored longterm therapy. We have to consider not only the effect but also side effects of the different drugs. The aim of the therapy is an optimal quality of life for the individual patient. To this end we have to avoid polypragmasia.     

Pharmacologic therapy for acute myocardial infarction. Which agent, how much, how soon, how long?

Is there any good reason to give intravenous nitroglycerin during evolving acute myocardial infarction? How about a beta blocker? Should an ACE inhibitor be started routinely within the first 24 hours of infarction? When is aspirin useful for suspected acute myocardial infarction? Is it safe in patients with contraindications to thrombolytic therapy? In this article, Dr Rapaport answers these and many more questions by summarizing findings of important studies and describing conclusions he has come to on the basis of his own clinical experience.     

Insufficient detrusor contractility: a urodynamic and morphologic entity in prostatism

OBJECTIVES: To analyze the urodynamic and ultrastructural characteristics of impaired detrusor contractility in patients with prostatism in comparison with lower urinary tract obstruction. METHODS: The study comprised 200 male patients (mean age 65.3 years) with prostatism submitted to a complete urodynamic study. An ultrastructural study was randomly performed in 40 patients and analyzed 600 detrusor muscle images to determine the smooth muscle cell and interstitial changes. Detrusor urodynamics were compared with the ultrastructural cell and interstitial changes of the bladder smooth muscle. RESULTS: Urinary symptoms or free flowmetry alone failed to predict detrusor urodynamics. Urodynamic diagnosis was based on the detrusor pressure-flow study. We observed ultrastructural degenerative cell changes with statistical significance in impaired detrusor contractility such as no branching and intertwining of cells, absence of caveoles, perinuclear degeneration with vacuolization, destructured myofilament system with diminished anchorage plates and collagen infiltrating the interstitium with loss of bladder muscle fascicle organization. CONCLUSIONS: Impaired detrusor contractility is a urodynamic diagnosis that should be taken into account in patients with prostatism. The diagnosis of this condition requires performing a pressure-flow study. Impaired detrusor contractility showed a morphological and ultrastructural correlation with degenerative changes of the bladder muscle.     

Pharmacologic treatment for children and adolescents with anxiety disorders

Pediatric anxiety disorders are common illnesses that, if left untreated, may induce academic, family, and interpersonal problems. Cognitive-behavioral techniques and other psychotherapeutic interventions may be adequate for the treatment of most anxiety disorders. For patients with severe symptoms or for whom psychotherapeutic approaches are not adequate, medications are indicated. Among the available medications, the SSRIs are currently the first choice; however, other medications, such as the benzodiazepines and the TCAs, may be used alone or sometimes in combination with the SSRIs. Caution with respect to medication interactions and side effects is indicated. In particular, long-term side effects in these medications have not been well studied.     

Pharmacologic pain. Management for cancer patients at home

Pain management is one of the most important responsibilities of the home care nurse serving cancer patients. Patients and caregivers often fear uncontrolled pain, and need frequent reassurance that effective pain control can be achieved. This article discusses the etiology and types of cancer pain, pain assessment, pharmacologic pain management interventions, and evaluation of pain management for home care patients.     

Value of the shape of the flowmetry curve in the study of prostatism

OBJECTIVE: To determine the relation of the urinary flow curve morphology of free flowmetry with the status of lower urinary tract dynamics. METHODS: A mathematical model was designed to fit the urinary flow curves to two models: a symmetrical and an asymmetrical model. Based on these models we analyzed the relationship between the presence or absence of obstruction and the type of model which better adjusted the urinary flow curves in a series of 85 males. RESULTS: The urinary flow curves corresponding to absence of obstruction adjusted significantly better to a symmetrical model than those corresponding to bladder outlet obstruction. No correlation was observed between the type of curve and bladder contractibility or type of urinary obstruction. CONCLUSIONS: There is a relationship between the form of the urinary flow curve and bladder obstruction. In the absence of obstruction, the urinary flow curves are more symmetrical.     

Pharmacologic treatment of exercise-induced asthma

Exercise-induced asthma (EIA) is a complex disorder affecting a sizeable minority of athletes. Proper pharmacologic management allows most every athlete at any level to participate with EIA. This article briefly addresses the pathophysiology, diagnosis, and basic treatment principles, including nonpharmacologic management for EIA. Most of the article details the current treatment strategies and provides information on experimental treatments being investigated. In addition, ergogenic concerns and problems in treating elite athletes are discussed.     

Pharmacologic modulation of autonomic tone: implications for the diabetic patient

The inhibitory effects of nitroglycerin (NTG) on platelet function and the mechanisms of inhibition have been studied in vitro, but not in vivo. Therefore, we have investigated the effects of NTG on platelet function in eight patients undergoing orthopaedic surgery. Simultaneous measurements of platelet aggregation and change in intracellular calcium concentrations were performed in Fura-2 loaded platelets using thrombin as a stimulator. Intraplatelet concentrations of cyclic 3',5'-guanine monophosphate (cGMP) were measured by radioimmunoassay, and the concentration of nitrite ion was also measured. Continuous i.v. infusion of NTG 4-8 micrograms kg-1 min-1 significantly inhibited platelet aggregation and the increase in intracellular Ca2+ concentration (first phase, mean 439.9 (SEM 68.7) vs 210.6 (38.7) nmol litre-1; second phase, 154.4 (19.8) vs 106.7 (18.0) nmol litre-1). The concentration of cGMP (from 0.633 (0.098) to 1.764 (0.578) pmol/10(9) platelets) and the concentration of nitrite ion (from 532.6 (17.6) to 724.4 (34.8) nmol litre-1) also increased significantly after infusion of NTG. The NTG concentration in plasma was of the order of 10(-8) mol litre-1. We have demonstrated that in vivo, NTG increased intraplatelet cGMP concentrations and inhibited platelet function; one mechanisms of this effect is likely to be related to nitric oxide liberation from NTG bioconversion.